Tracers / [131I]PSMA-769
[131I]PSMA-769
Also written as [I-131]PSMA-769
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Glu-ureido-based small-molecule PSMA inhibitor (Lys-urea-Glu pharmacophore with Gly-Tyr cleavable linker)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) inhibitor PMID 29803076
- Clinical application
- Detection and treatment of castration-resistant prostate cancer PMID 29803076
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC+SPE | 32.5 ± 0.1% | >95% | tin precursor 11 | 29803076 2018 Nucl Med Biol A solution of N-chlorosuccinimide (NCS) in methanol (1.5 mM; 100 μL), glacial acetic acid (20 μL) and 131I (40-100 MBq in 1-3 μL) in that order were added to 11 (50 μg) in a half-dram vial. — Compounds [131I]6 and [211At]6 were synthesized from 11 in overall radiochemical yields of 32.5 ± 0.1% (n = 4) and 22% (n = 1), respectively |
Need this precursor?We can point you to suppliers for [131I]PSMA-769, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 29803076. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29803076: 'tin precursor 11'.